Dashboard
Manage Tickers

OCUP Opus Genetics, Inc.

Nasdaq opusgtx.com


$ 1.89 $ -0.09 (-4.52 %)    

Friday, 17-Oct-2025 12:22:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 603.35 $ 5.74 (0.96 %)
DIA $ 461.66 $ 2.30 (0.5 %)
SPY $ 663.41 $ 3.94 (0.6 %)
TLT $ 91.10 $ -0.13 (-0.14 %)
GLD $ 387.82 $ -9.37 (-2.36 %)
$ 2.01
$ 2.00
$ 1.87 x 110
$ 1.89 x 366
$ 1.90 - $ 2.01
$ 0.65 - $ 2.16
585,272
na
120.42M
$ 0.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-08-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-30-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-21-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 03-07-2019 12-31-2018 10-K
28 11-02-2018 09-30-2018 10-Q
29 08-03-2018 06-30-2018 10-Q
30 05-04-2018 03-31-2018 10-Q
31 03-09-2018 12-31-2017 10-K
32 11-03-2017 09-30-2017 10-Q
33 08-04-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 02-24-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-14-2016 12-31-2015 10-K
40 11-02-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ophthalmic-biopharmaceutical-ocuphire-pharma-shifts-focus-to-gene-therapy-through-opus-genetics-stock-deal
Ophthalmic Biopharmaceutical Ocuphire Phar...
10/23/2024 19:25:45

Ocuphire Pharma acquires Opus Genetics, expanding its IRD gene therapy pipeline. The renamed company, Opus Genetics, will trade...

canaccord-genuity-maintains-buy-on-ocuphire-pharma-lowers-price-target-to-10
Canaccord Genuity Maintains Buy on Ocuphir...
10/23/2024 17:58:06

Canaccord Genuity analyst John Newman maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target from $1...

trading-halt-halt-status-updated-at-43000-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 4:30:...
10/22/2024 20:30:05

ocuphire-pharma-says-new-opgx-lca5-phase-12-6-month-data-demonstrate-safety-and-visual-improvement-in-early-onset-retinal-degeneration-company-will-seek-a-strategic-partner-to-continue-development-of-apx3330-an-oral-small-molecule-inhibitor-of-ref-1-for-the-treatment-of-non-proliferative-diabetic-retinopathy-projected-cash-runway-extended-into-2026
Ocuphire Pharma Says New OPGx-LCA5 Phase 1...
10/22/2024 20:17:55

Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited ...

ocuphire-pharma-announces-acquisition-of-opus-genetics-ocuphire-issued-52m-shares-of-its-common-stock-and-141k-shares-of-its-convertible-preferred-stock-to-existing-stockholders-of-opus-genetics-ocuphire-will-own-58-of-the-combined-companys-fully-diluted-capitalization-and-pre-acquisition-stockholders-of-opus-genetics-will-own-42-of-the-combined-companys-fully-diluted-capitalization
Ocuphire Pharma Announces Acquisition Of O...
10/22/2024 20:16:49

Terms of the AcquisitionIn connection with the acquisition, Ocuphire issued 5.2 million shares of its common stock and 14.1 tho...

trading-halt-halted-at-40100-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:01:00 p.m. ET - ...
10/22/2024 20:01:04

ocuphire-pharma-announces-publication-of-full-phase-3-results-of-ryzumvi---phentolamine-ophthalmic-solution-075-for-pharmacologically-induced-mydriasis-in-ophthalmology
Ocuphire Pharma Announces Publication Of F...
09/30/2024 12:02:27

Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercial...

ocuphire-pharma-initiates-vega-3-phase-3-trial-of-phentolamine-ophthalmic-solution-075-for-presbyopia-topline-data-expected-in-first-half-of-2025
Ocuphire Pharma Initiates VEGA-3 Phase 3 T...
09/05/2024 12:07:29

hc-wainwright--co-maintains-buy-on-ocuphire-pharma-lowers-price-target-to-18
HC Wainwright & Co. Maintains Buy on Ocuph...
08/15/2024 10:03:19

HC Wainwright & Co. analyst Matthew Caufield maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price tar...

canaccord-genuity-maintains-buy-on-ocuphire-pharma-maintains-18-price-target
Canaccord Genuity Maintains Buy on Ocuphir...
08/14/2024 13:56:23

Canaccord Genuity analyst John Newman maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $18 price target.

ocuphire-pharma-q2-eps-030-misses-024-estimate-sales-111m-miss-261m-estimate
Ocuphire Pharma Q2 EPS $(0.30) Misses $(0....
08/13/2024 12:20:14

Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0...

ocuphire-pharma-participates-in-arvo-sig-panel-and-asrs-42nd-annual-scientific-meeting-to-highlight-apx3330-for-diabetic-retinopathy
Ocuphire Pharma Participates In ARVO SIG P...
07/10/2024 12:15:11

CEO to participate in ARVO SIG panel on oral medications for retinal diseasesZETA-1 Phase 2 clinical trial subset analysis to b...

ocuphire-pharma-announces-upcoming-presentations-on-lead-candidate-apx3330-for-diabetic-retinopathy-at-clinical-trials-at-the-summit-on-june-8-and-retinal-imaging-biomarkers--endpoints-summit-june-25-27
Ocuphire Pharma Announces Upcoming Present...
06/06/2024 12:00:25

duos-technologies-and-2-other-stocks-under-3-insiders-are-buying
Duos Technologies And 2 Other Stocks Under...
05/22/2024 11:35:52

canaccord-genuity-maintains-buy-on-ocuphire-pharma-lowers-price-target-to-18
Canaccord Genuity Maintains Buy on Ocuphir...
05/13/2024 16:40:53

Canaccord Genuity analyst John Newman maintains Ocuphire Pharma (NASDAQ:OCUP) with a Buy and lowers the price target from $2...

hc-wainwright--co-reiterates-buy-on-ocuphire-pharma-maintains-20-price-target
HC Wainwright & Co. Reiterates Buy on Ocup...
05/13/2024 10:46:55

HC Wainwright & Co. analyst Matthew Caufield reiterates Ocuphire Pharma (NASDAQ:OCUP) with a Buy and maintains $20 price...

ocuphire-pharma-q1-2024-gaap-eps-029-misses-013-estimate
Ocuphire Pharma Q1 2024 GAAP EPS $(0.29) M...
05/10/2024 12:07:55

Ocuphire Pharma (NASDAQ:OCUP) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0...

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
04/11/2024 20:31:16

ocuphire-pharma-announces-first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-ophthalmic-solution-075-ps-for-the-treatment-of-decreased-visual-acuity-under-low-light-conditions-following-keratorefractive-surgery
Ocuphire Pharma Announces First Patient En...
04/11/2024 14:05:39

LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner ViatrisFARMINGTON HILLS, Mich., Apr...

Core News & Articles
Ocuphire Announces the US Commercial Launc...
04/01/2024 11:17:13

 Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION